Back to News
Market Impact: 0.4
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsProduct Launches
Iovance Biotherapeutics reported a record second quarter, generating nearly $100 million in revenue and a 56% margin. The company is expanding its tumor-infiltrating lymphocyte (TIL) therapy platform into multiple solid-tumor indications, supporting a stronger commercial and pipeline outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
IOVA0.85
More News
- AI safety efforts will require more compute, not less: experts
- Buffett Son Takes Chair as Berkshire Transition Ends
- SpaceX Nasdaq 100 weight to jump to 2.82% in quarterly rebalance -Bloomberg
- What does the EU have that the U.S. does not?
- Oracle Has Committed Hundreds of Billions to AI Data Centers. These 2 Industrial Stocks Will Power Them.
- From BFFs to open war: Better.com’s founder vs. the investor who replaced him